What is Phil?
Phil operates as a sophisticated software-driven therapy deployment platform designed to bridge the gap between pharmaceutical manufacturers and patient care. The company provides a comprehensive suite of digital tools that replace traditional, fragmented access and distribution models. By integrating patient access services, market access analytics, and flexible distribution frameworks, Phil enables healthcare stakeholders to deliver therapies more efficiently and affordably. Its platform serves as a vital digital stakeholder experience layer, ensuring that life-saving treatments reach patients with minimal friction, thereby addressing long-standing inefficiencies in the pharmaceutical industry.
How much funding has Phil raised?
Phil has raised a total of $176.1M across 6 funding rounds:
Other Financing Round
$2.1M
Series A
$10M
Series B
$25M
Series C
$23M
Series D
$56M
Debt
$60M
Other Financing Round (2015): $2.1M with participation from Eniac Ventures, Fabrice Grinda, Forerunner Ventures, Uncork Capital, FJ Labs, and Tom Williams
Series A (2017): $10M led by Forerunner Ventures, Uncork Capital, Eniac Ventures, Softtech VC, Crosslink Capital, Silicon Valley Bank, and Transmedia Capital
Series B (2019): $25M supported by Tarsadia Hotels, Uncork Capital, GreatPoint Energy, and Crosslink Capital
Series C (2021): $23M, investors not publicly disclosed
Series D (2021): $56M backed by Warburg Pincus
Debt (2025): $60M with participation from K2 HealthVentures
Key Investors in Phil
Warburg Pincus
Warburg Pincus LLC is a leading global private equity firm renowned for its expertise in growth investing, supporting management teams in building long-term, sustainable success.
K2 HealthVentures
K2 HealthVentures is an alternative investment firm focused on providing flexible, long-term financing solutions to innovative private and public companies in the life sciences and healthcare industries.
Forerunner Ventures
Forerunner Ventures partners with founders to build category-defining companies at the intersection of technology and human behavior, focusing on emerging consumer demands.
What's next for Phil?
Looking ahead, the strategic deployment of $60M will likely focus on deepening the platform's integration within the broader healthcare ecosystem. As the company moves beyond its initial growth phases, the focus shifts toward enhancing the scalability of its distribution models and expanding its footprint in the life sciences sector. The recent debt financing suggests a move toward optimizing the balance sheet to support long-term operational sustainability and market expansion. Phil is expected to continue refining its digital stakeholder experiences, potentially exploring new therapeutic areas where access barriers remain high, thereby cementing its role as an essential infrastructure provider in the global pharmaceutical market.
See full Phil company page
